TABLE 1.
Characteristic | Lyme disease patientsa |
Healthy controls (n = 26) | P value for all Lyme disease patients vs controlsb | ||||||
---|---|---|---|---|---|---|---|---|---|
PTLDS (n = 11) | Symptoms only (n = 29) | Return to health (n = 36) | Total (n = 76) |
P valueb |
|||||
P vs S | P vs R | S vs R | |||||||
% participants of female sex | 72.73 | 48.28 | 41.67 | 48.68 | 0.29 | 0.07 | 0.59 | 53.85 | 0.65 |
Age (yr) | 0.04 | 0.24 | 0.29 | 0.17 | |||||
Median | 43 | 54 | 53 | 53 | 57 | ||||
IQRc | 29–53 | 46–66 | 34–62 | 38–63 | 46–66 | ||||
Range | 20–64 | 20–75 | 20–77 | 20–77 | 22–73 | ||||
% non-Hispanic white participants | 81.82 | 96.55 | 94.44 | 93.42 | 0.18 | 0.23 | 1.00 | 88.46 | 0.42 |
Lyme disease participants were grouped by clinical outcome (PTLDS [P], symptoms only [S], and return to health [R]) using a previously published definition incorporating both persistent symptoms and functional impact (25).
Significance was determined by the chi-square or Fisher's exact test for female sex and non-Hispanic white and the Wilcoxon rank sum test for age.
IQR, interquartile range.